Download - Thrombolysis for acute ischaemic stroke 1: why do we still need to do randomised trials & IST3?
Thrombolysis for acute ischaemic stroke 1: why do we still need to
do randomised trials & IST3?
Professor Peter SandercockOn behalf of IST-3 Collaborative Group
and for Gruppo Italiano IST-3University of Edinburgh
Who SHOULD get thrombolysis with i.v. rt-PA ‘within licence’?
• Patient MUST be– able to be treated within 3 hours– aged under 80– not have a history of prior stroke + Diabetes– not have any of the standard exclusions– NIHSS < 25– No extensive infarction on CT
• There must be a discussion of risk/consent
Who ACTUALLY gets rt-PA for acute ischaemic stroke ‘within licence’ in Europe?
0
50
100
150
200
250
rt-P
A f
or
str
ok
e p
er
millio
n p
op
'n
FinlandSwedenAustriaNorwayCzech RepublicSloveniaBelgiumDenmarkSpainIcelandGermanyPortugalItalySlovakiaAustraliaNetherlandsUnited KingdomLithuaniaPolandFranceGreeceCroatiaHungaryRussia
SITS-MOST 29/1/2007
Why so much variability in clinical practice?
• Insufficient evidence base
• Licence does not apply to older people
• What to do after 3 hours?
• How to balance risk and benefit?
• No consensus on imaging– Which method: CT or MR?– How should CT or MR appearance influence
decision about thrombolysis?
Compare evidence base! Number of pts in randomised trials of thrombolysis vs control
in acute myocardial infarction
Total no. patients by 1994! 58,600
in acute ischaemic stroke
Total (all agents) 5,675
rt-PA 2,700
rt-PA < 3hrs 930
rt-PA aged > 80 years 42
Number of older patients with acute stroke per year
in UK
87,000 patients aged > 70 years
47,000 patients aged > 80 years
= A big problem for acute medical services!
rt-PA trials meta-analysis. Benefit declines with increasing time to treatment, but scope
for benefit up to 6h?
Benefit
Harm
3 hours 6 hours
Upper and lower 95% confidence limits
Line of no effect
NNT 10 ‘Grey area’NNT 10? > 30? or net
harm?
Risk of treatment: fatal haemorrhage 3%
Risk of NOT treating with rt-PA? Fatal deterioration due to swelling in large infarcts.
CT at 5hrs CT at 72 hrsEarly ischaemic change Swelling and midline shift
‘Area Grigia’ di incertezza: i.v. rt-PA promising but
unproven for patients who:• Present < 3hrs & do not exactly meet NINDS
criteria
• All patients 3-6hours
• Older patients (>75 years)
• Severe stroke, mild stroke…...
• Have subtle, early ischaemic change on CT
• Etc etc …
Current randomised trials of i.v. thrombolysis vs control
Trial Thrombolytic agent
Patient selection trial size & time window
EPITHET rt-PA Clinical, CT (+ DWI/PWI MRI) 3-6 hours 100 patients Results 2008
ECASS III rt-PA Clinical and CT; Age < 80 Stroke onset 3-4.5 hours 800 patients Results mid 2008
IST-3 rt-PA Clinical and CT; Ischaemic stroke 0-6 hours Up to 6000 patients
Thrombolysis for acute ischaemic stroke 2: progress with the trial. Where are we now, what is our
target?
Professor Peter SandercockOn behalf of IST-3 Collaborative Group
and for Gruppo Italiano IST-3University of Edinburgh
Main features of IST - 3
• International, multi-centre, Prospective, Randomised, Open, Blinded Endpoints study of i.v. rt-PA vs control.
• Primary outcome: the proportion of patients alive and independent at six months
• Simple central telephone randomisation with on-line minimisation to balance key prognostic factors.
• Web-based blinded detailed central review of all scans (ASPECTS, 1/3 MCA rule, dense MCA etc)
• Conducted to EU GCP standards.
IST-3 trial: randomisation
If patient fits main eligibility/exclusion criteria,
Clinician/patient/family discuss. If:
• Clear INDICATION FOR rt-PA TREAT (i.e. meets terms of current licence and patient agrees)
• Clear CONTRAINDICATION TO rt-PA DON’T TREAT
• rt-PA ‘PROMISING BUT UNPROVEN’ RANDOMISE
Recruitment by country: coppa del mondo
Country No. centres Pts. %
UK 34 377 38%
Poland 5 172 18%
Norway 12 125 13%
Italy 14 91 9%
Sweden
Australia
Belgium
14
10
3
73
69
56
7%
7%
6%
Austria
Canada
Mexico
1
1
1
8
5
1
1%
1%
-
Gruppo Italiano IST-3 : 2006Serie A (>5 patients)
Milano Ciccone 23
Citta Della Pieve Ricci 17
Aosta Botacchi 6
Serie B (<5 patients)
Citta di Castello Cenciarelli 2
Perugia, Silvestrini Agnelli 1
Gubbio Bigaroni 1
Foligno Brustengi 0
Negrar Adami 0
Vittoria Iemolo 0
Gruppo Italiano IST-3 : 2007
Serie A (>5 patients)Citta Della Pieve*
Niguarda, Milano
Aosta
27
25
13
Citta di Castello
Vibo Valentia*
5
5
Serie B (<5 patients)Foligno 4
Sacro Cuore Negrar Verona
Vittoria
Spoleto
Perugia, Silvestrini
4
3
2
1
Gubbio
Piacenza
1
1
*recruited a patient within last 30 days
Centri che stanno per partire
• Genova
• Modena
• Foggia
• Legnango
• Peschiera
• Verona
• Bologna
• Reggio Emilia
• Bari
Has the ‘area grigia’ changed since IST-3 began?
Characteristics of patients at baseline
Delay between stroke onset and randomisation
0
50
100
150
200
250
300
1 or less 1 to 2 2 to 3 3 to 4 4 to 5 >5Hours between stroke onset and randomisation
Num
ber o
f pat
ient
s
.
(Median = 4.1 hours)
0%10%20%30%40%50%60%70%80%90%
100%
1st 224 2nd 224 3rd 224 4th 224
0-3 hrs
3.1-6 hrs
Trends in type of patient recruited since trial began: Time to randomisation
No. patients recruited into trial
Age at randomisation
0
50
100
150
200
250
300
50 orunder
51-60 61-70 71-80 81-90 91-100 Over100
Age in years at randomisation
Nu
mb
er o
f p
atie
nts
.
Age at randomisation > 330 patients aged > 80 = increased world evidence base 8 x!
0%
10%20%
30%
40%50%
60%
70%
80%90%
100%
1st 224 2nd 224` 3rd 224 4th 224
> 80 years
< 80 years
Trends in type of patient recruited since trial began: age
No. patients recruited into trial
0%10%20%30%40%50%60%70%80%90%
100%
1st 224 2nd 224` 3rd 224 4th 224
POCI
LACI
PACI
TACI
No. patients recruited into trial
Trends in type of patient recruited since trial began: Infarct subtype
Expert’s opinion of randomisation CT*
• Acute ischaemic change 64%
• Periventricular lucencies 44%
• Normal 6%
*scans may show more than one abnormality
Frequency of hyperdense artery on baseline and follow-up CT
Present on baseline scan 152 (39%)
Present on follow-up scan 102 (26%)
Persisted (seen on 1st & 2nd scan) 88 (23%)
Present on baseline, disappeared by 2nd scan 64 (16%)
Has the ‘area grigia’ changed since IST- began?
NO
2007 report of the IST 3 Data Monitoring Committee
We reviewed analyses based on 896 randomised patients. We should like to commend the investigators for the high quality and completeness of the data, as well as the exemplary conduct of the trial. The DMC did not consider it necessary to recommend any change to the study protocol… we would encourage the investigators to make every effort to recruit all eligible patients so that reliable evidence emerges as rapidly as possible.
Professor Rory Collins, Chairman
Recruitment strategy: the future
• Focus efforts on countries already in trial
• Increase number of centres in these countries
• Work with existing centres to maintain or increase recruitment.
Recruitment strategy: the future. In Italy this means:
• Can your centre recruit enough so you move up (or you can join) Serie A in Gruppo Italiano IST-3?
• Can Italy move up in the coppa del mondo IST-3?
0
20
40
60
80
100
120
140
160
May
00
May
01
May
02
May
03
May
04
May
05
May
06
May
07
May
08
Randomisation date
Num
ber of centr
es
.
1 Oct 07: active centres
31 Dec 08: active centres
1 Oct 07: total centres
31 Dec 08: total centres
Projected total number of centres, and number of active centres
Sample size (MRC Protocol)
• with 1000 patients we could detect a 7% absolute difference in the primary outcome, which is consistent with the effect size among patients randomised within 3 hours of stroke in the Cochrane review.
• If 3500 patients were recruited, the trial could detect a 4% absolute difference in the primary outcome.
• With 6000 patients, mostly treated between 3 & 6 hours of onset, the trial could detect a 3% absolute difference in the primary outcome
Protocol version 1.92 September 2005
Recruitment IST3: Cumulative number of patients randomised
0
100
200
300
400
500
600
700
800
900
1000
May
200
0
Nov
200
0
May
200
1
Nov
200
1
May
200
2
Nov
200
2
May
200
3
Nov
200
3
May
200
4
Nov
200
4
May
200
5
Nov
200
5
May
200
6
Nov
200
6
May
200
7
Nov
200
7
Randomisation Date
Num
ber o
f pat
ient
s
.
Recruitment = 982 patients randomised by 30.11.07. Almost reached 1st target!
Hot news!
• We applied to MRC to extend trial to reach one of our targets
• UK Medical Research Council– Recognised the importance of the trial – agreed to this plan – given extra funds (~ €500,000),
• IST-3 can continue recruitment to mid 2011and report trial in 2012 if needed
Sample size (MRC Protocol)
• with 1000 patients we could detect a 7% absolute difference in the primary outcome, which is consistent with the effect size among patients randomised within 3 hours of stroke in the Cochrane review.
• If 3500 patients were recruited, the trial could detect a 4% absolute difference in the primary outcome.
• With 6000 patients, mostly treated between 3 & 6 hours of onset, the trial could detect a 3% absolute difference in the primary outcome
Protocol version 1.92 September 2005
With 3100, we could detect a 4.7%
benefit. NNT 21
New plan: recruit 3,100 by 2011
Third International Stroke Trial. A large randomised trial to answer the question:
can a wider variety of patients be treated?
Target: 3100 patients or more from ~ 100 centres in 14 Countries by 2011
Conclusions
• IST-3 asks very important questions– Who benefits?– By how much?– How to make best use of CT to select patients?
• It is the LAST CHANCE to get these data• We MUST go on• The approval by MRC = recognition of the
scientific importance of our work• Our data will influence clinical practice in the
REAL world!